A phase 1 trial of prizloncabtagene autoleucel, a CD19/CD20 CAR T-cell therapy for relapsed/refractory B-cell non-Hodgkin lymphoma
Blood · 03.04.2025 · 145 (14) · 1526-1535
DOI: 10.1182/blood.2024026401 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift Blood, erschienen am 03.04.2025. Verfasst von Wenjuan Yu und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China. Hauptthemen laut MEDLINE: Immunotherapy, Adoptive, Antigens, CD19, Lymphoma, B-Cell, Antigens, CD20. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Prizloncabtagene autoleucel (prizlon-cel), a novel bispecific chimeric antigen receptor T cell, targets and eliminates CD19/CD20-positive tumor cells. This phase 1, open-label study investigated the safety and efficacy of prizlon-cel in patients with relapsed/refractory B-cell non-Hodgkin lymphoma (R/R B-NHL). Patients with CD19 and/or CD20-positive R/R B-NHL received a 3-day lymphodepletion (cyclophosphamide: 300 mg/m2 per day; fludarabine: 30 mg/m2 per day) followed by an IV dose of prizlon-cel. The primary end points were dose-limiting toxicity (DLT) and incidence and severity of treatment-emergent adverse events (TEAEs). Secondary end points included overall response rate (ORR), duration of response (DOR), progression-free survival (PFS), and overall survival (OS). Of the 48 patients infused prizlon-cel, 44 had large B-cell lymphoma (LBCL). No patient experienced DLT. Cytokine release syndrome occurred in 93.8% of the patients, with only 1 case of grade 3. Immune effector cell-associated neurotoxicity syndrome occurred in 6.3% of patients, with no grade 3 or higher events. The most common grade 3 or higher TEAEs were neutropenia (83.3%) and leukopenia (50%). The ORR and complete response (CR) rates in all patients were 91.5% and 85.1%, respectively, and in LBCL patients, ORR was 90.7% with 86.0% CR. With median follow-up of 30.0 months, median DOR, PFS, and OS were all not reached. Kaplan-Meier estimate of 2-year DOR, PFS, and OS rates were 66.0%, 62.6%, and 76.5%, respectively. Prizlon-cel had a favorable safety profile and a high and durable response in patients with R/R B-NHL, suggesting a promising treatment option for patients with R/R B-NHL. These trials were registered at www.clinicaltrials.gov as #NCT04317885, #NCT04655677, #NCT04696432, and #NCT04693676.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Hematology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
- Department of Hematology, Tongji Hospital of Tongji University, Shanghai, China.
- Shanghai AbelZeta Ltd, Shanghai, China.
- Department of Hematology, Peking Union Medical College Hospital, Beijing, China.
- Department of Lymphoma, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.
- University of Maryland School of Medicine, Baltimore, MD.
ORCID-Profile: Yan Zhang
Zitieren
APA
Yu, W., Li, P., Zhou, L., Yang, M., Ye, S., Zhu, D., Huang, J., Yao, X., Zhang, Y., Li, L., Zhao, J., Zhu, K., Li, J., Zheng, C., Lan, L., Wan, H., Yao, Y., Zhang, H., Zhou, D., …, & Liang, A. (2025). A phase 1 trial of prizloncabtagene autoleucel, a CD19/CD20 CAR T-cell therapy for relapsed/refractory B-cell non-Hodgkin lymphoma. Blood, 145(14), 1526-1535. https://doi.org/10.1182/blood.2024026401
Vancouver
Yu W, Li P, Zhou L, Yang M, Ye S, Zhu D, et al. A phase 1 trial of prizloncabtagene autoleucel, a CD19/CD20 CAR T-cell therapy for relapsed/refractory B-cell non-Hodgkin lymphoma. Blood. 2025;145(14):1526-1535. doi:10.1182/blood.2024026401
BibTeX
@article{Yu2025,
author = {Yu, Wenjuan and Li, Ping and Zhou, Lili and Yang, Min and Ye, Shiguang and Zhu, Dan and Huang, Jiaqi and Yao, Xin and Zhang, Yan and Li, Lanfang and Zhao, Jing and Zhu, Kevin and Li, Jing and Zheng, Chengxiao and Lan, Liping and Wan, Hui and Yao, Yihong and Zhang, Huilai and Zhou, Daobin and Jin, Jie and Liang, Aibin},
title = {A phase 1 trial of prizloncabtagene autoleucel, a CD19/CD20 CAR T-cell therapy for relapsed/refractory B-cell non-Hodgkin lymphoma},
journal = {Blood},
year = {2025},
volume = {145},
number = {14},
pages = {1526--1535},
doi = {10.1182/blood.2024026401}
}
EUVIMED